- Price
- $212.17
- Day
- +0.54%
- Mkt Cap
- $10.92B
- 52W Range
- $101.11 – $260.19
- Volume
- 473.5K
- Beta
- 0.60
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
BLND, AXSM and BCML have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2026.
Read full article
ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
Read full article
Caxton Associates LLP bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,311 shares of the company's stock, valued at approximately $729,000. Other hedge funds have also made changes to their positions in
Read full article
LEN, AXSM and SAM have been added to the Zacks Rank #5 (Strong Sell) List on July 27, 2026.
Read full article
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Read full article
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
Read full article
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.
Read full article